UroGen Pharma Ltd’s recent filing unveils that its Chief Medical Officer Schoenberg Mark unloaded Company’s shares for reported $0.17 million on Mar 18 ’24. In the deal valued at $14.05 per share,12,000 shares were sold. As a result of this transaction, Schoenberg Mark now holds 139,437 shares worth roughly $1.86 million.
Then, Smith Jason Drew sold 4,993 shares, generating $78,590 in total proceeds. Upon selling the shares at $15.74, the General Counsel now owns 18,824 shares.
Before that, Schoenberg Mark sold 3,789 shares. UroGen Pharma Ltd shares valued at $59,639 were divested by the Chief Medical Officer at a price of $15.74 per share. As a result of the transaction, Schoenberg Mark now holds 149,423 shares, worth roughly $2.0 million.
Jefferies downgraded its UroGen Pharma Ltd [URGN] rating to a Hold from a a Buy in a research note published on February 08, 2023; the price target was decreased to $10 from $35. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in late April with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering URGN and reiterated its “Buy” recommendation on April 16, 2020. H.C. Wainwright maintained its rating on April 13, 2020. It rated URGN as “a Buy”.
Price Performance Review of URGN
On Tuesday, UroGen Pharma Ltd [NASDAQ:URGN] saw its stock jump 1.21% to $13.37. Over the last five days, the stock has lost -5.11%. UroGen Pharma Ltd shares have fallen nearly -10.87% since the year began. Nevertheless, the stocks have risen 51.93% over the past one year. While a 52-week high of $24.13 was reached on 02/16/24, a 52-week low of $8.57 was recorded on 04/02/24. SMA at 50 days reached $16.56, while 200 days put it at $14.93. A total of 0.2 million shares were traded, compared to the trading of 0.24 million shares in the previous session.
Levels Of Support And Resistance For URGN Stock
The 24-hour chart illustrates a support level at 13.08, which if violated will result in even more drops to 12.80. On the upside, there is a resistance level at 13.78. A further resistance level may holdings at 14.20. The Relative Strength Index (RSI) on the 14-day chart is 33.63, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.12, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 92.93%. Stochastics %K at 7.52% indicates the stock is a buying.
How much short interest is there in UroGen Pharma Ltd?
A steep rise in short interest was recorded in UroGen Pharma Ltd stocks on Mar 15, 2024, growing by 0.24 million shares to a total of 4.25 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 4.01 million shares. There was a rise of 5.65%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 13.48% of the overall stock float, the days-to-cover ratio (short ratio) rose to 12.84.
The most recent change occurred on January 09, 2020 when National Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $37 price target.
